Biologic Therapy of Ulcerative Colitis: Infliximab, Adlimumab, Golimumab
Anti-tumor necrosis factor α (anti-TNF-α) agents pose the latest entry into our arsenal compiled to fight ulcerative colitis (UC), a chronic inflammatory bowel disease for which causes are still elusive. Till now, however, among this class of drugs, only infliximab is authorized for use in UC. Infliximab survived the test of randomized clinical trials and the scrutiny of health authorities around the globe. Infliximab has been incorporated into clinical routine guidelines and is recommended to be used for induction and maintenance of remission in patients with moderately to severely active UC who had failed standard immunosuppressants. Furthermore, infliximab’s potential to induce mucosal healing and to avoid colectomy has been demonstrated. Early results also suggest the clinical efficacy of adalimumab in UC. Further data are awaited, which also applies to golimumab. This chapter summarizes the existing evidence on the efficacy of anti-TNF-α agents in UC and endeavors to discuss it in the context of clinical routine management.
KeywordsUlcerative colitis Biologics Anti-TNF-α Infliximab Adalimumab
- 2.Fuss IJ, Neurath M, Boirivant M, et al. Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn’s disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J Immunol. 1996;157:1261–70.PubMedGoogle Scholar
- 23.Lawson MM, Thomas AG, Akobeng AK. Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2006;3:CD005112.Google Scholar